CE mark of approval for cataract laser system

Article

The CE mark of approval has been given to OptiMedica's Catalys Precision Laser System.

The CE mark of approval has been given to OptiMedica's Catalys Precision Laser System.

The Catalys has been approved to deliver capsulotomy and lens fragmentation. OptiMedica are currently awaiting approval for corneal incisions - anticipated in the near future.

The laser system incorporates the use of a femtosecond laser and optical coherence tomography (OCT) imaging. The optical path to the patient's eye is optimized to guarantee stable system-patient attachment due to the Liquid Optics Interface. Catalys also offers a proprietary Integral Guidance system that ensures safe and precise femtosecond laser pulses during surgery. The graphical user interface is simple to use and reduces patient time under the dock.

Dr William Culbertson, Professor of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, USA, said, "The system's CE mark of approval is a tremendous milestone that rewards years of intense collaboration to deliver the greatest precision and best experience for both surgeon and patient."

Mark J. Forchette, OptiMedica's president and chief executive officer, added, "We are excited to enter this new stage in OptiMedica's history, and we look forward to introducing Catalys to markets around the world in the very near future."

The first shipment of the Catalys will be introduced to Europe late this year.

If you would like to read more on this system please click here for an article by Dr Jonathan Talamo that was published in April's print issue of OTEurope on his experiences with the system and his thoughts on femtosecond laser cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.